Tumor Cells and Diseases Related to Drug Treatment

Jie Shen, Yusong Liu, Hui Zhang

Abstract


At present, tumors especially malignancies, have become one of the most serious diseases that threaten human health. The use of chemotherapy, radiotherapy, surgery, biotherapy and integrated traditional Chinese and Western medicine is the most effective means of treating tumors. Among them, the application of new anti-tumor drugs, in improving the quality of life of cancer patients to extend the survival time, delay the development of the disease has played a huge role. In this paper, we reviewed the related research progress of tumor cells from the aspects of tumor features, related signal pathways, related genes, epigenetic modification, tumor stem cells and tumor microenvironment, so as to have a more comprehensive understanding of tumor and cell apoptosis.


Full Text:

PDF

References


Zheng Hong, Zhou Youjun. Anti-tumor drug research progress [J]. Chinese Journal of New Drugs and Clinical Medicine, 2005, 24 (2): 139- 142.

Wang Biyun. Targeted therapeutic effect on metastatic breast cancer [J] Chinese Journal of Cancer, 2003, 25 (2): 204 - 2051

Liu Chuan. Antineoplastic drugs Pixantrone [J]. Chinese Journal of New Drugs, 2004; 13 (8): 763.

Klotz L, Boccon-Gibod L, Shore ND, et al. The efficacy and safety of degarelix: a 12- month, comparative, randomized, open-label, parallel- group phase study in patientswith prostate cancer [J]. BJU Int, 2008, 102 (11):1531.

Liu Chuan. Hu Max-CD4 treatment of skin T cell lymphoma orphan drug status [J]. Chinese New Drugs Journal, 2004; 13 (12): 1180.

Liu Xiufeng, Qin Shukui, Wang Lin, et al. Clinical observation of a variety of advanced malignant tumors treated with Endu and chemotherapy [J]. Journal of Clinical Oncology, 2007, 12 (4): 241- 250.

Zhang Shige. Tumor targeted therapy of the progress and clinical evaluation [J]. Chinese Hospital Drug Evaluation and Analysis, 2009, 9 (1): 4-7.


Refbacks

  • There are currently no refbacks.




Creative Commons License

This site is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.